Market Cap 15.26B
Revenue (ttm) 4.37B
Net Income (ttm) -1.22B
EPS (ttm) N/A
PE Ratio 24.58
Forward PE 22.70
Profit Margin -27.97%
Debt to Equity Ratio 0.66
Volume 1,679,900
Avg Vol 1,699,494
Day's Range N/A - N/A
Shares Out 153.70M
Stochastic %K 93%
Beta 1.40
Analysts Sell
Price Target $110.69

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other g...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 858 202 4500
Fax: 858 202 4545
Address:
5200 Illumina Way, San Diego, United States
patten1962
patten1962 Oct. 4 at 11:32 AM
$PACB ●In 2028 $ILMN offered $1.2B to buy PacBio. ●That would be $8.00 per share according to Ai. ●Today the Company is in much better shape. ●PacBio is very undervalued! ●$TMO & $A are the logical companies for M&A. ●Institutional Ownership includes Ark, Softbank, Blackrock, Vanguard.
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 3:54 AM
$ILMN: Unusual Options Activity Alerted CALL flow observed 11x contracts at Strike price of $75 Exp on 12/19/2025 with Premium of $31K and showing BULLISH Sentiment
0 · Reply
highnihilism
highnihilism Oct. 3 at 5:50 PM
$ILMN Illumina Trades: 190 | Total $: 454.5 K | 0.28 × 90-Day Avg $: 1.63 M | Call $: 381.1 K | Put $: 73.5 K | Single-Leg: 79% | Multi-Leg: 21% $ELS Equity Lifestyle Properties Trades: 45 | Total $: 375.8 K | 9.18 × 90-Day Avg $: 40.9 K | Call $: 375.8 K | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% $BAX Baxter Intl Trades: 460 | Total $: 481.9 K | 0.83 × 90-Day Avg $: 580.9 K | Call $: 375.7 K | Put $: 106.2 K | Single-Leg: 91% | Multi-Leg: 9% $ITB iShares U.S. Home Construction Trades: 317 | Total $: 440.3 K | 0.22 × 90-Day Avg $: 2.0 M | Call $: 375.1 K | Put $: 65.2 K | Single-Leg: 89% | Multi-Leg: 11%
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:04 PM
$BIAF $ILMN $ARCT $URG Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 4:15 PM
Enter: $ILMN NOV 21 2025 $105 CALLS Buy in Price: $5.90 - $6.80 Take Profit: $9.32 Stop Bleeding: $5.98 ROI Potential: 37% Exit Within: 181 Minutes https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Oct. 3 at 1:13 PM
$ILMN just made a bold move with its new BioInsight division 🧬 The launch is designed to harness multiomic data, speed up drug discovery, and improve disease diagnosis — a powerful growth catalyst in the making. See the full breakdown here 👉 https://www.zacks.com/stock/news/2761336/ilmn-stock-set-to-benefit-from-the-launch-of-new-bioinsight-division?cid=sm-stocktwits-2-2761336-teaser-14592&ADID=SYND_STOCKTWITS_TWEET_2_2761336_TEASER_14592
0 · Reply
ZacksResearch
ZacksResearch Oct. 3 at 12:13 PM
$ILMN launches BioInsight — what it means for the stock's future 🚀 Shares surged 7.7% post-announcement, highlighting Illumina's strategic push into multiomics and AI-driven solutions for pharma and research under new leadership. With a strong earnings yield and recent gains, the momentum looks set to continue. Discover how BioInsight could drive ILMN's growth here 👉 https://www.zacks.com/stock/news/2761336/ilmn-stock-set-to-benefit-from-the-launch-of-new-bioinsight-division?cid=sm-stocktwits-2-2761336-body-14589&ADID=SYND_STOCKTWITS_TWEET_2_2761336_BODY_14589
0 · Reply
tievLeaf
tievLeaf Oct. 3 at 7:36 AM
$QSI there is a huge chance this goes to $10 by November just solely on it being the purest proteomic play in the market right now. Zoom out the chart. $RGTI $NVDA $RXRX $ILMN
0 · Reply
Brent24
Brent24 Oct. 2 at 5:33 PM
$GRAL The spinoff valuation from $ILMN never made sense. It was valuing the greatest MCED company out there trade at an insanely low EV. With $550M cash we still only trade at $1.5B enterprise value. Stupid cheap here. Chart will look like GEV in about a year.
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:03 PM
Barclays updates rating for Illumina ( $ILMN ) to Underweight, target set at 90 → 95.
0 · Reply
Latest News on ILMN
ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 8 days ago

ILMN Stock vs. IQV Stock

IQV


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 5 weeks ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL IONS MRNA RGEN


Illumina: The Stock Is Still Undervalued

Aug 4, 2025, 4:23 AM EDT - 2 months ago

Illumina: The Stock Is Still Undervalued


Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 1:25 AM EDT - 2 months ago

Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript


Illumina Stock: What Went Wrong And Why It's Best To Stay Away

Jul 17, 2025, 7:45 AM EDT - 2 months ago

Illumina Stock: What Went Wrong And Why It's Best To Stay Away


Illumina To Webcast Upcoming Investor Conference

May 14, 2025, 4:05 PM EDT - 5 months ago

Illumina To Webcast Upcoming Investor Conference


Illumina Analysts Lower Their Forecasts After Q1 Results

May 12, 2025, 11:28 AM EDT - 5 months ago

Illumina Analysts Lower Their Forecasts After Q1 Results


Illumina: Multiple Headwinds Point To Limited Upside In 2025

May 10, 2025, 10:58 PM EDT - 5 months ago

Illumina: Multiple Headwinds Point To Limited Upside In 2025


Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:01 PM EDT - 5 months ago

Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript


Is Illumina Undervalued After An 83% Drop In Its Stock Price?

Mar 27, 2025, 8:35 AM EDT - 6 months ago

Is Illumina Undervalued After An 83% Drop In Its Stock Price?


Activist Investor Meister to Join Illumina's Board

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Activist Investor Meister to Join Illumina's Board


Illumina addresses recent developments in China

Mar 10, 2025, 4:10 PM EDT - 7 months ago

Illumina addresses recent developments in China


China bans imports of Illumina's gene sequencers

Mar 4, 2025, 12:57 AM EST - 7 months ago

China bans imports of Illumina's gene sequencers


patten1962
patten1962 Oct. 4 at 11:32 AM
$PACB ●In 2028 $ILMN offered $1.2B to buy PacBio. ●That would be $8.00 per share according to Ai. ●Today the Company is in much better shape. ●PacBio is very undervalued! ●$TMO & $A are the logical companies for M&A. ●Institutional Ownership includes Ark, Softbank, Blackrock, Vanguard.
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 3:54 AM
$ILMN: Unusual Options Activity Alerted CALL flow observed 11x contracts at Strike price of $75 Exp on 12/19/2025 with Premium of $31K and showing BULLISH Sentiment
0 · Reply
highnihilism
highnihilism Oct. 3 at 5:50 PM
$ILMN Illumina Trades: 190 | Total $: 454.5 K | 0.28 × 90-Day Avg $: 1.63 M | Call $: 381.1 K | Put $: 73.5 K | Single-Leg: 79% | Multi-Leg: 21% $ELS Equity Lifestyle Properties Trades: 45 | Total $: 375.8 K | 9.18 × 90-Day Avg $: 40.9 K | Call $: 375.8 K | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% $BAX Baxter Intl Trades: 460 | Total $: 481.9 K | 0.83 × 90-Day Avg $: 580.9 K | Call $: 375.7 K | Put $: 106.2 K | Single-Leg: 91% | Multi-Leg: 9% $ITB iShares U.S. Home Construction Trades: 317 | Total $: 440.3 K | 0.22 × 90-Day Avg $: 2.0 M | Call $: 375.1 K | Put $: 65.2 K | Single-Leg: 89% | Multi-Leg: 11%
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:04 PM
$BIAF $ILMN $ARCT $URG Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 4:15 PM
Enter: $ILMN NOV 21 2025 $105 CALLS Buy in Price: $5.90 - $6.80 Take Profit: $9.32 Stop Bleeding: $5.98 ROI Potential: 37% Exit Within: 181 Minutes https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Oct. 3 at 1:13 PM
$ILMN just made a bold move with its new BioInsight division 🧬 The launch is designed to harness multiomic data, speed up drug discovery, and improve disease diagnosis — a powerful growth catalyst in the making. See the full breakdown here 👉 https://www.zacks.com/stock/news/2761336/ilmn-stock-set-to-benefit-from-the-launch-of-new-bioinsight-division?cid=sm-stocktwits-2-2761336-teaser-14592&ADID=SYND_STOCKTWITS_TWEET_2_2761336_TEASER_14592
0 · Reply
ZacksResearch
ZacksResearch Oct. 3 at 12:13 PM
$ILMN launches BioInsight — what it means for the stock's future 🚀 Shares surged 7.7% post-announcement, highlighting Illumina's strategic push into multiomics and AI-driven solutions for pharma and research under new leadership. With a strong earnings yield and recent gains, the momentum looks set to continue. Discover how BioInsight could drive ILMN's growth here 👉 https://www.zacks.com/stock/news/2761336/ilmn-stock-set-to-benefit-from-the-launch-of-new-bioinsight-division?cid=sm-stocktwits-2-2761336-body-14589&ADID=SYND_STOCKTWITS_TWEET_2_2761336_BODY_14589
0 · Reply
tievLeaf
tievLeaf Oct. 3 at 7:36 AM
$QSI there is a huge chance this goes to $10 by November just solely on it being the purest proteomic play in the market right now. Zoom out the chart. $RGTI $NVDA $RXRX $ILMN
0 · Reply
Brent24
Brent24 Oct. 2 at 5:33 PM
$GRAL The spinoff valuation from $ILMN never made sense. It was valuing the greatest MCED company out there trade at an insanely low EV. With $550M cash we still only trade at $1.5B enterprise value. Stupid cheap here. Chart will look like GEV in about a year.
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:03 PM
Barclays updates rating for Illumina ( $ILMN ) to Underweight, target set at 90 → 95.
0 · Reply
tievLeaf
tievLeaf Oct. 2 at 1:25 PM
$QSI to all folks at $NVDA $RXRX and $ILMN. Maybe the 50mil investor that did its investment in RXRX back in 2023 is the same one after all for QSI lol which is Nvidia, abit too much of a coincidence? we all know what happened to RXRX when it was revealed that Nvidia invested in them.
0 · Reply
JoeCoolTrader
JoeCoolTrader Oct. 2 at 12:14 AM
$ILMN - looks interesting. Could see a gap fill at 122. $SPY
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 1 at 10:57 PM
$ILMN Share Price: $102.29 Contract Selected: Jan 16, 2026 $100 Calls Buy Zone: $10.12 – $12.50 Target Zone: $16.90 – $20.65 Potential Upside: 58% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
grnback
grnback Oct. 1 at 6:58 PM
$QSI The proteomics universe is heating up. $ILMN $TMO $TXG
0 · Reply
Woodman7
Woodman7 Oct. 1 at 6:31 PM
$CLNN $EXAS $ILMN $PACB - my health care stocks seem like a Good place to be today!
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 1 at 6:29 PM
Illumina Stock Surged 6% Today – Here’s Why $ILMN $DWSH $MODL https://stocktwits.com/news/equity/markets/illumina-stock-surges-after-launching-bioinsight/chCYgtvR3O3
0 · Reply
Da_Big_Sweed
Da_Big_Sweed Oct. 1 at 2:31 PM
$ILMN wow
0 · Reply
tievLeaf
tievLeaf Oct. 1 at 1:44 PM
$QSI Not just that, they were also honored with the Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Next-Generation Protein Sequencing in 2024. This is the purest play in the proteomic market and hopefully folks at QC $RGTI $IONQ $QBTS and other biotech sectors folks see this. It will blow up before it reaches the typical retail masses. Highly likely by November. $ILMN https://ir.quantum-si.com/news-releases/news-release-details/quantum-si-honored-frost-sullivans-2024-technology-innovation
0 · Reply
davis8uni
davis8uni Oct. 1 at 2:40 AM
0 · Reply
davis8uni
davis8uni Sep. 30 at 4:38 PM
0 · Reply
davis8uni
davis8uni Sep. 30 at 9:14 AM
0 · Reply
highnihilism
highnihilism Sep. 30 at 8:08 AM
$DDD 3D Systems: 683 trades, $249K vs $104K avg (2.40x). $236K calls / $13K puts. $ETOR Etoro Group: 163 trades, $307K vs $1.01M avg (0.30x). $236K calls / $70K puts. $ILMN Illumina: 250 trades, $293K vs $1.8M avg (0.16x). $236K calls / $57K puts. $GSK GSK: 1,138 trades, $438K vs $548K avg (0.80x). $235K calls / $203K puts.
0 · Reply